Servier joins the Act4Nature International initiative
Servier strengthens its commitment to biodiversity
as part of its corporate social responsibility strategy
PARIS, France, December 1st, 2021 – Servier an international pharmaceutical group, has joined Act4Nature International, an initiative for voluntary commitment to biodiversity. Launched in 2018 by the EpE (Entreprises pour l’Environnement) association, and numerous partners, this alliance between companies, public authorities, scientists and environmental associations has one ambition: to create a genuine international collective dynamic to protect, enhance and restore biodiversity, thanks in particular to the involvement of CEOs from all sectors.
Through this action, Servier has adhered to the ten shared commitments defined by Act4Nature and has also made individual commitments that are in line with the Group’s CSR strategy and are based on four areas: assessing and reducing the impact of products on biodiversity, reducing the impact of sites on biodiversity, raising awareness and developing skills on biodiversity issues and participating in biodiversity protection projects. These four priority areas are the result of an impact study carried out within the Group in 2021 by an expert body.
The SMART (specific, measurable, attainable, relevant, time-bound) nature of these commitments was validated by a committee of partners including environmental NGOs, business networks and scientific partners.
For Olivier Laureau, President of the Servier Group, and signatory to Act4Nature’s commitment: “The links between health and the environment are a major global issue. Servier is committed to Act4Nature International and reaffirms the importance of preserving biodiversity in its CSR strategy. At Servier, we are collectively monitoring the impact of our activities on the ecosystem.”
For Vincent Minvielle, CSR Director of Servier Group: “By joining Act4Nature, we reaffirm Servier Group’s commitment to biodiversity with specific actions that respond to the challenges facing the planet. Among the actions initiated: reducing the environmental impact of our industrial chemical synthesis, through the deployment of ‘Green Score’, an internal evaluation tool, and obtaining in the future the BiodiverCity® label for the Servier Research and Development Institute, which will open its doors in 2023 in Paris-Saclay.”
Servier is deploying an ambitious, proactive, global Corporate Social Responsibility (CSR) strategy that is integrated into the Group’s strategy. Corporate Social Responsibility is not only a driver of overall performance, but also a means for commitment, enabling the Group to strengthen its positive social, economic and environmental impact.
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: servier.com
|Follow us on Social Media:|
Servier press contacts: